<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05044117</url>
  </required_header>
  <id_info>
    <org_study_id>CMHN</org_study_id>
    <nct_id>NCT05044117</nct_id>
  </id_info>
  <brief_title>Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN)</brief_title>
  <official_title>Single-agent Capecitabine as Metronomic Chemotherapy in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (CMHN)：A Phase III, Multicentre, Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fujian Medical University Union Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangzhou Panyu Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Central Hospital of Yongzhou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First People's Hospital of Huaihua</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hanzhong Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yichang Central People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Affiliated Hospital of Guangdong Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangmen Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether the addition of metronomic capecitabine&#xD;
      to the standard treatment can improve prognosis in locoregionally advanced head and neck&#xD;
      squamous cell carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The standard treatment for resectable locoregionally advanced squamous cell carcinoma of the&#xD;
      head and the neck (LAHNSCC) is a regimen consisting of radical surgery plus radiotherapy or&#xD;
      concurrent chemoradiotherapy. And induction chemotherapy plus radical radiotherapy or&#xD;
      concurrent chemoradiotherapy is also recommended for locoregionally advanced squamous cell&#xD;
      carcinoma of larynx and hypopharynx. With the extensive application of comprehensive&#xD;
      treatment, the 5-year overall survival of LAHNSCC has not reached 50% yet. So, it is urgent&#xD;
      to explore a regimen with high efficiency and low toxicity on the basis of existing standard&#xD;
      treatment.&#xD;
&#xD;
      Two retrospective studies found that the metronomic use of orally administered fluorouracil&#xD;
      drugs following the reference treatment significantly improved prognosis in LAHNSCC. And&#xD;
      capecitabine is one kind of the oral fluorouracil drugs, which has high efficiency and low&#xD;
      toxicity. Indeed, metronomic capecitabine maintenance was shown to be effective in patients&#xD;
      with breast cancer, colorectal cancer, and nasopharyngeal carcinoma in phase III trials.&#xD;
&#xD;
      The abovementioned studies suggested the promising use of metronomic capecitabine in LAHNSCC.&#xD;
      However, there has been no randomized trials in this field. Therefore, we initiated a&#xD;
      randomized phase III trial to investigate the efficacy and safety of the addition of&#xD;
      metronomic capecitabine to the standard treatment in LAHNSCC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">October 2026</completion_date>
  <primary_completion_date type="Anticipated">October 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>PFS will be measured from the day of randomization until treatment failure, death from any cause, or the last follow-up visit, whichever occurred first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>OS will be measured from the day of randomization until death due to any cause, or the last follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant failure-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>DFFS will be measured from the day of randomization until death until distant metastasis, or the last follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Locoregional failure-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>LRFFS will be measured from the day of randomization until death until local and/or regional recurrence, or the last follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The incidence of capecitabine-related and other adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported quality-of-life score</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Patient reported quality of life would be evaluated using the Quality of Life Questionnaire-Core 30 module (QLQ-C30). The score is between 0-100, and the higher score means worse quality of life.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Clinical observation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The standard treatment followed by clinical observation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metronomic capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The standard treatment followed by a maintenance therapy with capecitabine (650 mg/m2 bid, d1-21, q3w) for 1 year.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Metronomic capecitabine (650 mg/m2 bid, d1-21, q3w) for 1 year</description>
    <arm_group_label>Metronomic capecitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Performance status of ECOG grade 0 or 1.&#xD;
&#xD;
          2. Tumor staged as III-IV (as defined by the 8th AJCC edition), with newly histologically&#xD;
             confirmed squamous cell carcinoma of oral cavity, oropharynx, larynx or hypopharynx.&#xD;
&#xD;
          3. Complete one of the following treatments:&#xD;
&#xD;
               1. Radical surgery plus radiotherapy or concurrent chemoradiotherapy&#xD;
&#xD;
               2. Neoadjuvant therapy plus radical radiotherapy or concurrent chemoradiotherapy&#xD;
&#xD;
          4. Postoperative radiotherapy started within 4 to 8 weeks after completion of radical&#xD;
             surgery.&#xD;
&#xD;
          5. Within 4 to 6 weeks after completion of the last radiation dose.&#xD;
&#xD;
          6. No clinical evidence of persistent locoregional disease or distant metastases before&#xD;
             enrollment.&#xD;
&#xD;
          7. Adequate hematologic (neutrophil count &gt; 1.5×10^9/L, hemoglobin &gt; 90g/L and platelet&#xD;
             count &gt; 100×10^9/L), hepatic (alanine aminotransferase, aspartate aminotransferase ≤&#xD;
             1.5×ULN, bilirubin ≤ 1.5×ULN, alkaline phosphatase ≤ 2.5×ULN) and renal function&#xD;
             (creatinine clearance ≥ 50 ml/min).&#xD;
&#xD;
          8. Patients must be appraised of the investigational nature of the study and provide&#xD;
             written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. p16 positive.&#xD;
&#xD;
          2. Patients who were known to be intolerable or allergic to capecitabine.&#xD;
&#xD;
          3. Illness that would interfere with oral medication, including dysphagia, chronic&#xD;
             diarrhea, or ileus.&#xD;
&#xD;
          4. Prior malignancy except adequately treated basal cell or squamous cell skin cancer, in&#xD;
             situ cervical cancer.&#xD;
&#xD;
          5. Pregnancy or lactation (consider pregnancy test in women of child-bearing age and&#xD;
             emphasize effective contraception during the treatment period).&#xD;
&#xD;
          6. Prior surgery, chemotherapy, radiotherapy or other anti-tumor treatments (except&#xD;
             diagnostic) to primary tumor or nodes before the standard therapy.&#xD;
&#xD;
          7. Patients who received surgery treatment, biotherapy or immunotherapy during&#xD;
             radiotherapy.&#xD;
&#xD;
          8. Patients who are receiving or highly likely to receive other chemotherapy treatment,&#xD;
             biotherapy or immunotherapy after radiotherapy.&#xD;
&#xD;
          9. Any severe intercurrent disease, which may bring unacceptable risk or affect the&#xD;
             compliance of the trial, for example, unstable cardiac disease requiring treatment,&#xD;
             renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose &gt;&#xD;
             1.5×ULN), and emotional disturbance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ying Sun, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ying Sun, M.D.</last_name>
    <phone>+86-(020)-87343816</phone>
    <email>sunying@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 4, 2021</study_first_submitted>
  <study_first_submitted_qc>September 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2021</study_first_posted>
  <last_update_submitted>October 17, 2021</last_update_submitted>
  <last_update_submitted_qc>October 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Ying Sun</investigator_full_name>
    <investigator_title>Vice president</investigator_title>
  </responsible_party>
  <keyword>head and neck squamous cell carcinoma</keyword>
  <keyword>locoregionally advanced disease</keyword>
  <keyword>metronomic capecitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

